MedPage Today1d
Chronic Pain Sufferers No Stranger to Depression and Anxiety
Among 347,468 individuals who had lived with persistent pain for over 3 months, clinical symptoms of depression and anxiety ...
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Clinical Pain Advisor1d
FDA Fast Tracks Investigational Nonopioid Treatment for Acute Pain
The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.
‘Revolutionary’: James Island pharmacist weighs in on newly approved medication
A James Island pharmacist is looking to the future of pain management thanks to the Food and Drug Administration approving a new treatment.
BioPharma Dive1d
Vertex’s new pain drug gets first coverage nod from major insurer
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
Vertex’s non-opioid pain drug gets some UnitedHealth coverage
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Vertex non-opioid pain drug picked up by UnitedHealth
Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...
Business Wire2d
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Trea…
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Fierce Biotech2d
Tris' next-gen pain drug completes trio of clinical wins, setting up push to FDA
Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...
Investing Snacks3d
Vertex’s Journavx Poised for Big Outpatient Market Win
Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...
2 Minute Medicine4d
Vertex: non-opioid pain reliever Journavx shows success in post operative pain control
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...